VEGF Trap-Eye received unanimous recommendation from an FDA drugs advisory committee for approval. The drug, now called EYLEA, is due for final FDA decision on August 20, 2011.
The advantage of this fusion protein (aflibercept) is that it will be administered every two months, after the initial three monthly doses. The present VEGF blocking drugs usually require ongoing monthly injections. A generally favorable safety profile was observed in the two Phase 3 trials of the drug.
SEE FULL STORY [10]
|
|
Links:
[1] http://www.macula.org/category/tag/aflibercept
[2] http://www.macula.org/category/disease/amd
[3] http://www.macula.org/category/treatment/drug-therapy
[4] http://www.macula.org/category/tag/eylea
[5] http://www.macula.org/category/disease/neovascularization
[6] http://www.macula.org/category/categories/possible-future-therapies
[7] http://www.macula.org/category/categories/research-studies
[8] http://www.macula.org/category/anatomy/macula
[9] http://www.macula.org/category/anatomy/retina
[10] http://www.medicalnewstoday.com/releases/228937.php